Literature DB >> 29869151

[What rheumatologists can learn from gastroenterologists].

S Fischer1, C Beyer2, M F Neurath2.   

Abstract

BACKGROUND: Chronic inflammatory diseases are complex disorders, which due to their multitude of manifestations require interdisciplinary treatment.
OBJECTIVE: The aim of this article is to provide a brief overview of current strategies and innovations for chronic inflammatory bowel diseases.
METHODS: A literature search was carried out in PubMed.
RESULTS: Shared pathophysiological pathways in chronic inflammatory diseases sometimes lead to common targets in treatment; however, there are also relevant specific differences with respect to treatment.
CONCLUSION: Due to the many extraintestinal organ manifestations, chronic inflammatory bowel diseases require interdisciplinary treatment.

Entities:  

Keywords:  Arthritis; Calprotectin; Chronic inflammatory bowel diseases; Glucocorticoids; Microbiota

Mesh:

Year:  2018        PMID: 29869151     DOI: 10.1007/s00393-018-0482-x

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  35 in total

1.  Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial.

Authors:  Wolfgang Hueber; Bruce E Sands; Steve Lewitzky; Marc Vandemeulebroecke; Walter Reinisch; Peter D R Higgins; Jan Wehkamp; Brian G Feagan; Michael D Yao; Marek Karczewski; Jacek Karczewski; Nicole Pezous; Stephan Bek; Gerard Bruin; Bjoern Mellgard; Claudia Berger; Marco Londei; Arthur P Bertolino; Gervais Tougas; Simon P L Travis
Journal:  Gut       Date:  2012-05-17       Impact factor: 23.059

2.  Molecular imaging of mucosal α4β7 integrin expression with the fluorescent anti-adhesion antibody vedolizumab in Crohn's disease.

Authors:  Timo Rath; Christian Bojarski; Markus F Neurath; Raja Atreya
Journal:  Gastrointest Endosc       Date:  2017-01-27       Impact factor: 9.427

3.  Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial.

Authors:  Séverine Vermeire; Stefan Schreiber; Robert Petryka; Tanja Kuehbacher; Xavier Hebuterne; Xavier Roblin; Maria Klopocka; Adrian Goldis; Maria Wisniewska-Jarosinska; Andrey Baranovsky; Robert Sike; Kremena Stoyanova; Chantal Tasset; Annegret Van der Aa; Pille Harrison
Journal:  Lancet       Date:  2016-12-15       Impact factor: 79.321

Review 4.  New therapies for inflammatory bowel disease: from the bench to the bedside.

Authors:  Silvio Danese
Journal:  Gut       Date:  2011-11-23       Impact factor: 23.059

5.  Asymptomatic sacroiliitis in inflammatory bowel disease. Assessment by computed tomography.

Authors:  N McEniff; S Eustace; C McCarthy; M O'Malley; C A O'Morain; S Hamilton
Journal:  Clin Imaging       Date:  1995 Oct-Dec       Impact factor: 1.605

6.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

7.  Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.

Authors:  Franck Carbonnel; Jean Frédéric Colombel; Jérome Filippi; Konstantinos H Katsanos; Laurent Peyrin-Biroulet; Mathieu Allez; Maria Nachury; Gottfried Novacek; Silvio Danese; Vered Abitbol; Fabrizio Bossa; Jacques Moreau; Gilles Bommelaer; Arnaud Bourreille; Mathurin Fumery; Xavier Roblin; Walter Reinisch; Yoram Bouhnik; Hedia Brixi; Philippe Seksik; Georgia Malamut; Martti Färkkilä; Baya Coulibaly; Olivier Dewit; Edouard Louis; Dominique Deplanque; Pierre Michetti; Hélène Sarter; David Laharie
Journal:  Gastroenterology       Date:  2015-11-26       Impact factor: 22.682

8.  Briakinumab for treatment of Crohn's disease: results of a randomized trial.

Authors:  Remo Panaccione; William J Sandborn; Glenn L Gordon; Scott D Lee; Alan Safdi; Shahriar Sedghi; Brian G Feagan; Stephen Hanauer; Walter Reinisch; John F Valentine; Bidan Huang; Roberto Carcereri
Journal:  Inflamm Bowel Dis       Date:  2015-06       Impact factor: 5.325

9.  Dual binding capacity of mucosal immunoblasts to mucosal and synovial endothelium in humans: dissection of the molecular mechanisms.

Authors:  M Salmi; D P Andrew; E C Butcher; S Jalkanen
Journal:  J Exp Med       Date:  1995-01-01       Impact factor: 14.307

10.  Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis.

Authors:  Raja Atreya; Stuart Bloom; Franco Scaldaferri; Viviana Gerardi; Charlotte Admyre; Åsa Karlsson; Thomas Knittel; Jan Kowalski; Milan Lukas; Robert Löfberg; Stephane Nancey; Robert Petryka; Grazyna Rydzewska; Robert Schnabel; Ursula Seidler; Markus F Neurath; Christopher Hawkey
Journal:  J Crohns Colitis       Date:  2016-05-20       Impact factor: 9.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.